journal
MENU ▼
Read by QxMD icon Read
search

Leukemia & Lymphoma

journal
https://www.readbyqxmd.com/read/28406352/using-low-dose-homoharringtonine-and-cytarabine-in-combination-with-granulocyte-colony-stimulating-factor-in-a-priming-induction-therapy-for-acute-myeloid-leukemia-a-retrospective-study-of-29-cases-in-china
#1
Haihui Liu, Jingjing Zhang, Saisai Ren, Mingtai Chen, Lulu Liu, Hao Zhang
No abstract text is available yet for this article.
April 13, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28402206/second-cancers-in-survivors-of-plasmacytoma-of-bone-in-the-u-s-a-a-seer-database-analysis
#2
Mohamed Abd El-Fattah
No abstract text is available yet for this article.
April 12, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28402164/hijaking-the-epigenome-in-leukemia-and-lymphoma
#3
Amanda C Drennan, Lixin Rui
The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by receptors of diverse cytokines, growth factors, and other related molecules. Many of these receptors transmit anti-apoptosis, proliferation, and differentiation signals that are critical for normal hematopoiesis and immune response. However, the JAK/STAT signaling pathway is deregulated in many hematologic malignancies, and as such is co-opted by malignant cells to promote their survival and proliferation...
April 12, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28402163/bortezomib-melphalan-and-prednisone-in-elderly-relapsed-refractory-multiple-myeloma-patients-update-of-multicenter-open-label-phase-1-2-study
#4
Sara Grammatico, Sara Bringhen, Federico Vozella, Agostina Siniscalchi, Mario Boccadoro, Maria Teresa Petrucci
No abstract text is available yet for this article.
April 12, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28402154/glucose-6-phosphate-dehydrogenase-deficiency-and-risk-of-invasive-fungal-disease-in-patients-with-acute-myeloid-leukemia
#5
Marco Sanna, Giovanni Caocci, Antonio Ledda, Federica Orrù, Claudio Fozza, Paola Deias, Gianni Tidore, Fausto Dore, Giorgio La Nasa
Invasive fungal diseases (IFD) are still a leading cause of morbidity and mortality in patients with acute myeloid leukemia (AML). Glucose-6-phosphate dehydrogenase is an enzyme that leads to the production of NADPH, required to destroy microorganisms in the respiratory burst reaction of white blood cells. We evaluated the role of G6PD deficiency in susceptibility of IFD in 108 AML patients undergoing intensive chemotherapy. In all, 28 patients harbored G6PD deficiency (G6PD-), whereas 80 were normal (G6PD +)...
April 12, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28402152/daptomycin-nonsusceptible-vancomycin-resistant-enterococcus-bloodstream-infections-in-patients-with-hematological-malignancies-risk-factors-and-outcomes
#6
Erica S Herc, Carol A Kauffman, Bernard L Marini, Anthony J Perissinotti, Marisa H Miceli
Daptomycin is typically the treatment of choice for vancomycin resistant Enterococcus (VRE) bloodstream infections (BSI) in patients with hematological malignancies, but increasingly daptomycin nonsusceptible VRE are being reported. We reviewed our experience with daptomycin nonsusceptible VRE BSI among patients with hematological malignancies. We compared risk factors and outcomes of 20 patients with daptomycin nonsusceptible VRE BSI (case patients) with 40 matched control patients with daptomycin susceptible VRE BSI...
April 12, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28395585/a-phase-ii-bayesian-sequential-clinical-trial-in-advanced-waldenstr%C3%A3-m-macroglobulinemia-patients-treated-with-bortezomib-interest-of-addition-of-dexamethasone
#7
Véronique Leblond, Pierre Morel, Marie-Sarah Dilhuidy, Xavier Leleu, Carole Soussain, Stéphane Leprête, Brigitte Dreyfus, Caroline Dartigeas, Béatrice Mahé, Bruno Anglaret, Brigitte Pégourié, Caroline Besson, Thérèse Aurran, Anne Vekhoff, Olivier Tournilhac, Anne Banos, Hervé Oya, Julie Lejeune, Maya Ouzegdouh, Sylvie Chevret
In patients with advanced Waldenström macroglobulinemia (WM), overall response rate (ORR) and median progression-free survival (PFS) achieved with bortezomib alone and bortezomib rituximab combination were 27-85% and 7.9 months, and 81% and 16.4 months, respectively. We checked the role of dexamethasone in combination with bortezomib by enrolling in a phase II trial 34 patients with relapsed/refractory WM. Bortezomib (1.3 mg/m(2) IV D1, 4, 8, and 11 every 21 days) was used for six cycles. In non-responding patients, dexamethasone (20 mg daily for two days) was added to each infusion after the second cycle...
April 10, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28395566/wt1-protein-is-cleaved-by-caspase-3-in-apoptotic-leukemic-cells
#8
Jichen Ruan, Shenmeng Gao, Junjun Yang, Haiying Li, He Huang, Xiaoqun Zheng
The aberrant overexpression of Wilms' tumor-1 gene (WT1) plays an important role in blast cell survival and resistance to chemotherapy in acute myeloid leukemia (AML). Here, we found in chemotherapeutic drug etoposide-induced apoptosis, WT1 protein was cleaved into smaller fragment by caspase-3 in leukemic cells. The cleavage was blocked by pan-caspase inhibitor and special caspase-3 inhibitor, suggesting that caspase-3 might cleave WT1 protein. Furthermore, recombinant active caspase-3 cleaved the Flag-WT1 and GST-WT1 proteins in vitro...
April 10, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28395565/regression-of-methotrexate-resistant-aids-related-primary-central-nervous-system-lymphoma-with-lenalidomide-plus-combination-anti-retroviral-therapy
#9
Neel K Gupta, Chia-Ching Wang, Gabriel N Mannis, John-Paul J Yu, James L Rubenstein
No abstract text is available yet for this article.
April 10, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28394191/the-parp-inhibitor-olaparib-enhances-the-cytotoxicity-of-combined-gemcitabine-busulfan-and-melphalan-in-lymphoma-cells
#10
Benigno C Valdez, Yang Li, David Murray, Yan Liu, Yago Nieto, Richard E Champlin, Borje S Andersson
The combination of gemcitabine (Gem), busulfan (Bu), and melphalan (Mel) is a promising regimen for autologous stem-cell transplantation (SCT) for lymphomas. To further improve the efficacy of [Gem + Bu + Mel], we added poly(ADP-ribose) polymerase (PARP) inhibitor olaparib (Ola). We hypothesized that Ola would inhibit the repair of damaged DNA caused by [Gem + Bu + Mel]. Exposure of J45.01 and Toledo cell lines to IC10-20 of individual drug inhibited proliferation by 6-16%; [Gem + Bu + Mel] by 20-27%; and [Gem + Bu + Mel + Ola] by 61-67%...
April 10, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28394181/a-novel-recurrent-copy-number-loss-region-on-6q23-3-in-mds-related-myeloid-malignancy-patients-with-stable-survival-conditions
#11
Kun Chi, Yang Li, Lan Xu, Xuefeng Wang
Metaphase cytogenetics (MC) karyotyping is a fundamental way to approach cytogenetic pathogenesis of MDS-related myeloid malignancies. However, in some patients, the results are normal while the patients often show discrepancies in survival conditions. To explain this question, we analyzed CytoScan™ HD array results of 20 MC-normal/failure patients who were followed up for three years. Exon sequencing was performed in genes RUNX1, TP53, ASXL1, and TET2. The array enabled the detection of additional aberrations in 16 (80%) patients...
April 10, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28393658/interactions-between-snps-affecting-inflammatory-response-genes-are-associated-with-multiple-myeloma-disease-risk-and-survival
#12
Kaspar René Nielsen, Maria Rodrigo-Domingo, Rudi Steffensen, John Baech, Kim S Bergkvist, Liesbeth Oosterhof, Alexander Schmitz, Julie Støve Bødker, Preben Johansen, Ulla Vogel, Anette Vangsted, Karen Dybkær, Martin Bøgsted, Hans Erik Johnsen
The origin of multiple myeloma depends on interactions with stromal cells in the course of normal B-cell differentiation and evolution of immunity. The concept of the present study is that genes involved in MM pathogenesis, such as immune response genes, can be identified by screening for single-nucleotide polymorphisms (SNPs) involved in the immune response and a subsequent statistical analysis that focusses on the association of SNPs, certain haplotypes or SNP-SNP interactions with MM risk and prognosis. We genotyped 348 Danish patients and 355 controls for 13 SNPs located in the TNFA, IL-4, IL-6, IL-10 and CHI3L1 gene promoters...
April 9, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28393584/corrigendum
#13
(no author information available yet)
No abstract text is available yet for this article.
April 9, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28393576/analysis-of-anticoagulation-strategies-for-venous-thromboembolism-during-severe-thrombocytopenia-in-patients-with-hematologic-malignancies-a-retrospective-cohort
#14
Damon E Houghton, Nigel S Key, Neil A Zakai, Jeffrey P Laux, Thomas C Shea, Stephan Moll
The safety and efficacy of anticoagulation for venous thromboembolism (VTE) at times of severe thrombocytopenia is unclear. In this retrospective study, we evaluated patients with hematologic malignancy and either (1) acute or chronic VTE on anticoagulation before platelet count dropped below 50 × 10(9)/L or (2) acute VTE occurring while platelets were <50 × 10(9)/L. In 78 eligible patients, the primary outcomes of time to recurrent VTE or clinically significant bleeding within 100 d were compared by management strategy...
April 9, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28372509/fc%C3%AE-riib-expression-in-early-stage-chronic-lymphocytic-leukemia
#15
Rosa Bosch, Alba Mora, Eva Puy Vicente, Gerardo Ferrer, Sonia Jansà, Rajendra Damle, Sergey Gorlatov, Kanti Rai, Emili Montserrat, Josep Nomdedeu, Marta Pratcorona, Laura Blanco, Silvana Saavedra, Ana Garrido, Albert Esquirol, Irene Garcia, Miquel Granell, Rodrigo Martino, Julio Delgado, Jorge Sierra, Nicholas Chiorazzi, Carol Moreno
In normal B-cells, B-cell antigen receptor (BCR) signaling can be negatively regulated by the low-affinity receptor FcγRIIb (CD32b). To better understand the role of FcγRIIb in chronic lymphocytic leukemia (CLL), we correlated its expression on 155 samples from newly-diagnosed Binet A patients with clinical characteristics and outcome. FcγRIIb expression was similar in normal B-cells and leukemic cells, this being heterogenous among patients and within CLL clones. FcγRIIb expression did not correlate with well known prognostic markers [disease stage, serum beta-2 microglobulin (B2M), IGHV mutational status, expression of ZAP-70 and CD38, and cytogenetics] except for a weak concordance with CD49d...
April 4, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28367723/gene-expression-analysis-of-hypersensitivity-to-mosquito-bite-chronic-active-ebv-infection-and-nk-t-lymphoma-leukemia
#16
Kana Washio, Takashi Oka, Lamia Abdalkader, Michiko Muraoka, Akira Shimada, Megumi Oda, Hiaki Sato, Katsuyoshi Takata, Yoshitoyo Kagami, Norio Shimizu, Seiichi Kato, Hiroshi Kimura, Kazunori Nishizaki, Tadashi Yoshino, Hirokazu Tsukahara
The human herpes virus, Epstein-Barr virus (EBV), is a known oncogenic virus and plays important roles in life-threatening T/NK-cell lymphoproliferative disorders (T/NK-cell LPD) such as hypersensitivity to mosquito bite (HMB), chronic active EBV infection (CAEBV), and NK/T-cell lymphoma/leukemia. During the clinical courses of HMB and CAEBV, patients frequently develop malignant lymphomas and the diseases passively progress sequentially. In the present study, gene expression of CD16((-))CD56((+))-, EBV((+)) HMB, CAEBV, NK-lymphoma, and NK-leukemia cell lines, which were established from patients, was analyzed using oligonucleotide microarrays and compared to that of CD56(bright)CD16(dim/-) NK cells from healthy donors...
April 3, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28367720/three-different-hematologists-three-different-answers-how-should-we-treat-concurrent-systemic-and-central-nervous-system-lymphoma
#17
Allison A Barraclough, Chan Yoon Cheah
No abstract text is available yet for this article.
April 3, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28367681/do-polymorphisms-in-mdr1-and-cyp3a5-genes-influence-the-risk-of-cytogenetic-relapse-in-patients-with-chronic-myeloid-leukemia-on-imatinib-therapy
#18
Natarajan Harivenkatesh, Lalit Kumar, Sameer Bakhshi, Atul Sharma, Madhulika Kabra, Thirumurthy Velpandian, Ajay Gogia, Shivaram S Shastri, Yogendra Kumar Gupta
Influence of polymorphisms in the genes coding for imatinib transporters and metabolizing enzymes on cytogenetic relapse in patients with chronic myeloid leukemia (CML) is not known. One hundred and four patients (52 cases with cytogenetic relapse and 52 controls without relapse) with chronic-phase CML on imatinib therapy and have completed 5 years of follow-up were enrolled. The following single nucleotide polymorphisms (SNPs) were genotyped; C1236T, C3435T, G2677T/A in MDR1 gene and A6986G in CYP3A5 gene, using PCR-RFLP method and validated by direct gene sequencing...
April 3, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28367668/genesis-of-new-allele-at-locus-d2s1360-in-leukemia-patient
#19
Blanka Robesova, Ivana Jeziskova, Marta Krejci, Jiri Mayer, Dana Dvorakova
No abstract text is available yet for this article.
April 3, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28367662/adverse-drug-reactions-after-intravenous-rituximab-infusion-are-more-common-in-hematologic-malignancies-than-in-autoimmune-disorders-and-can-be-predicted-by-the-combination-of-few-clinical-and-laboratory-parameters-results-from-a-retrospective-multicenter-study
#20
Giovanni D'Arena, Vittorio Simeon, Luca Laurenti, Michele Cimminiello, Idanna Innocenti, Michele Gilio, Angela Padula, Maria Luigia Vigliotti, Sonya De Lorenzo, Giacomo Loseto, Anna Passarelli, Matteo Nicola Dario Di Minno, Marco Tucci, Vincenzo De Feo, Fiorella D'Auria, Francesco Silvestris, Giovanni Di Minno, Pellegrino Musto
Rituximab is an effective treatment for CD20 + B-cell malignancies and autoimmune disorders. However, adverse drug reactions (ADRs) may occur after rituximab infusion, causing, in rare cases, its discontinuation. In this multicenter, retrospective study, among 374 patients treated with rituximab i.v., 23.5% experienced ADRs. Mean follow-up was 20.6 months (range 8-135). Overall, ADRs were significantly more frequent in non-Hodgkin lymphomas (NHL) and chronic lymphocytic leukemias (25-35.9%), than in autoimmune diseases (9...
April 3, 2017: Leukemia & Lymphoma
journal
journal
30440
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"